• 2024
  Cui S, Faure M, Wei Y, CALCOCO2/NDP52 associates with RAB9 to initiate an antiviral response to hepatitis B virus infection through a lysosomal degradation pathway., Autophagy 2024 May; (): 1-3.
• 2023
  Cui S, Xia T, Zhao J, Ren X, Wu T, Kameni M, Guo X, He L, Guo J, Duperray-Susini A, Levillayer F, Collard JM, Zhong J, Pan L, Tangy F, Vidalain PO, Zhou D, Jiu Y, Faure M, Wei Y, NDP52 mediates an antiviral response to hepatitis B virus infection through Rab9-dependent lysosomal degradation pathway., Nat Commun 2023 Dec; 14(1): 8440.
• 2022
  Benjamin Vesin 1 , Pierre Authié 1 , Catherine Blanc 1 , Ingrid Fert 1 , Amandine Noirat 1 , Fabien Le Chevalier 1 , Yu Wei 1 , Min-Wen Ku 1 , Kirill Nemirov 1 , François Anna 1 , David Hardy 2 , Cyril Planchais 3 , Hugo Mouquet 3 , Françoise Guinet 4 , Pierre Charneau 1 , Laleh Majlessi 1 , Maryline Bourgine 1, Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters, Vaccines (Basel).
• 2016
  Altinel K, Hashimoto K, Wei Y, Neuveut C, Gupta I, Suzuki AM, Dos Santos A, Moreau P, Xia T, Kojima S, Kato S, Takikawa Y, Hidaka I, Shimizu M, Matsuura T, Tsubota A, Ikeda H, Nagoshi S, Suzuki H, Michel ML, Samuel D, Buendia MA, Faivre J, Carninci P, Single-nucleotide-resolution mapping of HBV promoters in infected human livers and hepatocellular carcinoma, J. Virol. 2016 Sep;.
• 2015
  Tebbi A, Levillayer F, Jouvion G, Fiette L, Soubigou G, Varet H, Boudjadja N, Cairo S, Hashimoto K, Suzuki AM, Carninci P, Carissimo A, di Bernardo D, Wei Y, Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress, Carcinogenesis 2016 Jan;37(1):39-48.
• 2013
  Dahan J, Nouët Y, Jouvion G, Levillayer F, Adib-Conquy M, Cassard-Doulcier AM, Tebbi A, Blanc F, Remy L, Chen J, Cairo S, Werts C, Si-Tahar M, Tordjmann T, Buendia MA, Wei Y, , LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis., Mol Cell Biol 2013 Aug; 33(16): 3299-308.
• 2013
  Brun J, Fromigué O, Dieudonné FX, Marty C, Chen J, Dahan J, Wei Y, Marie PJ, The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b, Bone 2013 Mar;53(1):6-12.
• 2013
  Xia T, Lévy L, Levillayer F, Jia B, Li G, Neuveut C, Buendia MA, Lan K, Wei Y, The four and a half LIM-only protein 2 (FHL2) activates transforming growth factor β (TGF-β) signaling by regulating ubiquitination of the E3 ligase Arkadia, J. Biol. Chem. 2013 Jan;288(3):1785-94.
• 2012
  Nouët Y, Dahan J, Labalette C, Levillayer F, Julien B, Jouvion G, Cairo S, Vives FL, Ribeiro A, Huerre M, Colnot S, Perret C, Nhieu JT, Tordjmann T, Buendia MA, Wei Y, The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis, J. Hepatol. 2012 Nov;57(5):1029-36.
• 2010
  Wei Y, Neuveut C, Tiollais P, Buendia MA, Molecular biology of the hepatitis B virus and role of the X gene, Pathol. Biol. 2010 Aug;58(4):267-72.
• 2010
  Labalette C, Nouët Y, Levillayer F, Colnot S, Chen J, Claude V, Huerre M, Perret C, Buendia MA, Wei Y, Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice, PLoS ONE 2010;5(4):e10371.
• 2008
  Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, Pontoglio M, Strick-Marchand H, Levillayer F, Nouet Y, Rickman D, Gauthier F, Branchereau S, Brugières L, Laithier V, Bouvier R, Boman F, Basso G, Michiels JF, Hofman P, Arbez-Gindre F, Jouan H, Rousselet-Chapeau MC, Berrebi D, Marcellin L, Plenat F, Zachar D, Joubert M, Selves J, Pasquier D, Bioulac-Sage P, Grotzer M, Childs M, Fabre M, Buendia MA, Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer, Cancer Cell 2008 Dec;14(6):471-84.
• 2008
  Labalette C, Nouët Y, Levillayer F, Armengol C, Renard CA, Soubigou G, Xia T, Buendia MA, Wei Y, The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways, PLoS ONE 2008;3(11):e3761.
• 2008
  Labalette C, Nouët Y, Sobczak-Thepot J, Armengol C, Levillayer F, Gendron MC, Renard CA, Regnault B, Chen J, Buendia MA, Wei Y, The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation, J. Biol. Chem. 2008 May;283(22):15201-8.
• 2007
  Renard CA, Labalette C, Armengol C, Cougot D, Wei Y, Cairo S, Pineau P, Neuveut C, de Reyniès A, Dejean A, Perret C, Buendia MA, Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer, Cancer Res. 2007 Feb;67(3):901-10.
• 2006
  Paul C, Lacroix M, Iankova I, Julien E, Schäfer BW, Labalette C, Wei Y, Le Cam A, Le Cam L, Sardet C, The LIM-only protein FHL2 is a negative regulator of E4F1, Oncogene 2006 Sep;25(40):5475-84.
• 2003
  Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA, Identification of the LIM protein FHL2 as a coactivator of beta-catenin, J. Biol. Chem. 2003 Feb;278(7):5188-94.
• 2002
  Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA, Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features, Hepatology 2002 Sep;36(3):692-701.
• 2002
  Lévy L, Renard CA, Wei Y, Buendia MA, Genetic alterations and oncogenic pathways in hepatocellular carcinoma, Ann. N. Y. Acad. Sci. 2002 Jun;963:21-36.
• 2000
  Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA, Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas, Oncogene 2000 Jan;19(4):498-504.
• 1999
  Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA, Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation, Am. J. Pathol. 1999 Sep;155(3):703-10.